| Literature DB >> 24298172 |
Guusje Collin1, René S Kahn, Marcel A de Reus, Wiepke Cahn, Martijn P van den Heuvel.
Abstract
Schizophrenia has been conceptualized as a disorder of brain connectivity. Recent studies suggest that brain connectivity may be disproportionally impaired among the so-called rich club. This small core of densely interconnected hub regions has been hypothesized to form an important infrastructure for global brain communication and integration of information across different systems of the brain. Given the heritable nature of the illness, we hypothesized that connectivity disturbances, including abnormal rich club connectivity, may be related to familial vulnerability for schizophrenia. To test this hypothesis, both schizophrenia patients and unaffected siblings of patients were investigated. Rich club organization was examined in networks derived from diffusion-weighted imaging in 40 schizophrenia patients, 54 unaffected siblings of patients, and 51 healthy control subjects. Connectivity between rich club hubs was differentially reduced across groups (P = .014), such that it was highest in controls, intermediate in siblings (7.9% reduced relative to controls), and lowest in patients (19.6% reduced compared to controls). Furthermore, in patients, lower levels of rich club connectivity were found to be related to longer duration of illness and worse overall functioning. Together, these findings suggest that impaired rich club connectivity is related to familial, possibly reflecting genetic, vulnerability for schizophrenia. Our findings support a central role for abnormal rich club organization in the etiology of schizophrenia.Entities:
Keywords: brain network; connectome; diffusion-weighted imaging; familial vulnerability
Mesh:
Year: 2013 PMID: 24298172 PMCID: PMC3932089 DOI: 10.1093/schbul/sbt162
Source DB: PubMed Journal: Schizophr Bull ISSN: 0586-7614 Impact factor: 9.306
Demographic and Clinical Characteristics
| Controls ( | Siblings ( | Patients ( |
| |
|---|---|---|---|---|
| Age, mean (SD) | 29.4 (8.6) | 28.4 (6.8) | 30.6 (6.1) | NS |
| Gender, M/F | 22/29 | 19/35 | 36/4a | <.0001 |
| Psychiatric diagnosis | ||||
| Schizophrenia, | — | — | 31 (75.6) | — |
| Schizoaffective disorder, | — | — | 6 (14.6) | — |
| Otherb, | — | — | 3 (9.8) | — |
| PANSS symptoms | ||||
| Total, mean (SD) [range] | — | — | 46.9 (12.4) [30–83] | — |
| Positive, mean (SD) [range] | — | — | 10.6 (3.8) [7–24] | — |
| Negative, mean (SD) [range] | — | — | 12.6 (3.9) [7–23] | — |
| General, mean (SD) [range] | — | — | 23.9 (6.2) [16–42] | — |
| CAPE subclinical symptoms (frequency) | ||||
| Total, mean (SD) [range] | 10.5 (7.6) [0–31] | 11.0 (8.1) [0–38] | — | NS |
| Positive, mean (SD) [range] | 1.8 (2.4) [0–9] | 2.0 (2.1) [0–9] | — | NS |
| Negative, mean (SD) [range] | 5.1 (3.8) [0–15] | 5.3 (4.8) [0–25] | — | NS |
| Depressive, mean (SD) [range] | 3.5 (2.6) [0–12] | 3.6 (2.8) [0–13] | — | NS |
| Age of illness onset, mean (SD) | — | — | 22.5 (4.9) | — |
| Duration of illness in years, mean (SD) | — | — | 7.6 (4.0) | — |
| Global functioningc, mean (SD) | — | — | 5.8 (3.2) | — |
| Antipsychotic medication | ||||
| Typical/atypical/none/unknown, | — | — | 3/30/2/5 | — |
| Chlorpromazine equivalent dose, mean (SD) [range]e | — | — | 275.9 (161.0) [50–625] | — |
| Cannabis, lifetime abuse/dependency, | 2 (3.9) | 1 (1.9) | 4 (10) | NS |
| Urine drug screening at time of scan | ||||
| Any, | 3 (5.9) | 3 (5.6) | 3 (7.5) | NS |
| Cocaine, | 0 (0) | 1 (1.9) | 2 (5.0) | NS |
| Amphetamine, | 0 (0) | 0 (0) | 0 (0) | NS |
| Cannabis, | 3 (5.9) | 2 (3.7) | 1 (2.5) | NS |
| Recent or lifetime substance use, | 4 (7.8) | 4 (7.4) | 6 (15.0) | NS |
Note: NS, not significant; PANSS, Positive and Negative Syndrome Scale; CAPE, Community assessment of psychic experiences; CAN, Camberwell Assessment of Need.
aIndicates the subject group that is statistically different from other subject groups.
bOther diagnoses include schizophreniform disorder and psychotic disorder not otherwise specified.
cGlobal functioning as measured by the total number of met and unmet needs on the CAN.
d“Typical” includes haloperidol, flupenthixol and perfenazine; “atypical” includes risperidone, olanzapine, quetiapine, clozapine, aripiprazole; “none” is no current antipsychotic treatment.
eChlorpromazine equivalent doses were calculated using conversion rates (risperidone 66:1, olanzapine 20:1, quetiapine 1.3:1, clozapine 1:1, haloperidol 33:1, aripiprazole 13.3:1, flupenthixol 50:1, perfenazine 12.5:1).[39]
Fig. 1.Rich club. Schematic representation of a group-averaged reconstructed structural brain network. Nodes are categorized into rich club and nonrich club peripheral nodes and connections are color coded to indicate rich club, feeder, or local connections.
Fig. 2.Rich club, feeder, and local connectivity. Bar graphs indicate connectivity strength (ie, sum of reconstructed fibers), for rich club, feeder, and local connections. A significant ordered difference, such that controls > siblings > patients, was found for rich club connectivity (P = .014).
Fig. 3.Node-specific abnormalities. Cortical regions for which differential reductions (ie, controls > siblings > patients) in S , E , and C were found. Regions are color-coded according to P-value, with dark blue regions surviving FDR-correction, marking the bilateral superior frontal and rostral anterior cingulate gyri, left medial orbitofrontal and inferior temporal gyri, and right precentral and insular gyri, (all q < .05).
Fig. 4.Component of differentially affected connections. Schematic representation of a group-averaged brain network, showing a component of connections with differentially reduced connectivity strength, ie, controls > siblings > patients (P = .007). Cortical regions are represented as nodes, with node coloring indicating rich club or peripheral nodes; bold black lines indicating the connections belonging to the subnetwork. Importantly, no individual connection can be declared significant alone, only the subnetwork as a whole.[57]